Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028
The global continuous bioprocessing market is projected to reach USD 599 million by 2028 from USD 218 million in 2023, at a CAGR of 22.4% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing adoption of continuous bioprocessing among CDMOs and CMOs. Continuous bioprocessing is becoming more popular among CDMOs and CMOs for the production of biopharmaceuticals. These organizations face increasing pressure to manufacture biopharmaceuticals faster and more efficiently, and continuous bioprocessing can help them meet this demand. Additionally, continuous bioprocessing is moving into larger-scale projects and new therapeutic areas. This trend is expected to drive the growth of the continuous bioprocessing market in the coming years.
“The monoclonal antibodies segment accounted for the largest share by application in 2022.”
In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater productivity & flexibility and reduce costs.
“The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028.”
The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property rights for most new medicines and conduct over half the world's R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the continuous bioprocessing market by product (chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products), by scale of operation (commercial operations and clinical operations), by process (downstream bioprocess and upstream bioprocess), by application (monoclonal antibodies, vaccines, cell and gene therapy, and other applications), by end users (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the continuous bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the continuous bioprocessing market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall continuous bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“The monoclonal antibodies segment accounted for the largest share by application in 2022.”
In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater productivity & flexibility and reduce costs.
“The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028.”
The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property rights for most new medicines and conduct over half the world's R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Sartorius AG (Germany)
- Thermo Fisher Scientific Inc. (US)
- Repligen Corporation (US)
- Merck KGaA (Germany)
- 3M Company (US)
- Getinge AB (Sweden)
- Eppendorf SE (Germany)
- Corning Incorporated (US)
- Entegris (US)
- FUJIFILM Holdings Corporation (Japan)
- Meissner filtration products, Inc. (US)
- Kьhner AG (Switzerland)
- Esco Lifesciences Group (Singapore)
- SATAKE MultiMix Corporation (Japan)
- Bionet (Spain)
- Stobbe Group (Switzerland)
- bbi-biotech GmbH (Germany)
- OmniBRx Biotechnologies (India)
- Cell Culture Company, LLC (US)
- Pierre Guйrin (France)
- Solida Biotech GmbH (Germany)
- Zellwerk GmbH (Germany)
- 3D Biotek, LLC (US)
- FiberCell Systems Inc. (US)
This research report categorizes the continuous bioprocessing market by product (chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products), by scale of operation (commercial operations and clinical operations), by process (downstream bioprocess and upstream bioprocess), by application (monoclonal antibodies, vaccines, cell and gene therapy, and other applications), by end users (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the continuous bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the continuous bioprocessing market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall continuous bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous bioprocessing), restraints (high capital investment to limit entry for small players and stringent regulatory requirements), opportunities (high growth potential of emerging economies and PAT-enabled optimization of continuous bioprocessing), and Challenges (integration into existing manufacturing facilities and operational challenges) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the continuous bioprocessing market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the continuous bioprocessing market
- Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kьhner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), and among others in the market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SEGMENTATION
FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)
FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022)
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH FORECAST
FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023–2028)
FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 DATA TRIANGULATION & MARKET BREAKDOWN
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION)
FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET
4 PREMIUM INSIGHTS
4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW
FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT
FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION
FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2 MARKET DYNAMICS
TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising demand for biopharmaceuticals
5.2.1.2 Growing adoption among CDMOs and CMOs
5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode
5.2.1.4 Favorable regulatory & government support for innovative technologies
5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing
5.2.2 RESTRAINTS
5.2.2.1 High capital investments to limit entry for smaller players
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
5.2.3.2 PAT-enabled optimization of continuous bioprocessing
5.2.4 CHALLENGES
5.2.4.1 Integration into existing manufacturing facilities
5.2.4.2 Operational challenges
5.3 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022)
TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022)
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & PRODUCT DEVELOPMENT
5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY
5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET
TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE)
5.8 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013–SEPTEMBER 2023)
5.9 KEY CONFERENCES AND EVENTS
TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023?2024)
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2 REGULATORY GUIDELINES
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 TECHNOLOGY ANALYSIS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS
5.14 KEY BUYING CRITERIA, BY END USER
FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET
6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES
6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET
TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 FILTRATION SYSTEMS AND DEVICES
6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET
TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 BIOREACTORS
6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND
TABLE 27 BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS
6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.6 OTHER PRODUCTS
TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION
7.1 INTRODUCTION
TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
7.2 COMMERCIAL OPERATIONS
7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET
TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
7.3 CLINICAL OPERATIONS
7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET
TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS
8.1 INTRODUCTION
TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
8.2 DOWNSTREAM BIOPROCESS
8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET
TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
8.3 UPSTREAM BIOPROCESS
8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH
TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 MONOCLONAL ANTIBODIES
9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET
TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
9.3 VACCINES
9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET
TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
9.4 CELL & GENE THERAPY
9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND
TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
9.5 OTHER APPLICATIONS
TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 CONTINUOUS BIOPROCESSING MARKET, BY END USER
10.1 INTRODUCTION
TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET
TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
10.4 ACADEMIC & RESEARCH INSTITUTES
10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH
TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
11 CONTINUOUS BIOPROCESSING MARKET, BY REGION
11.1 INTRODUCTION
TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 High biopharmaceutical R&D spending to drive market
TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market
TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing initiatives for life sciences research to boost demand
TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 UK
11.3.2.1 Favorable government support for biotech clusters to propel market
TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising demand for mAbs and biologics to drive market
TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Growth in pharma & biopharma industries to boost demand
TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing R&D funding by academic institutes to support market growth
TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Government support and rising private investments to drive market growth
TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth
TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growth in pharmaceutical industry to boost demand
TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 SOUTH KOREA
11.4.4.1 Rising focus on quality manufacturing practices to drive market
TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 ASIA PACIFIC: RECESSION IMPACT
11.5 LATIN AMERICA
TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Rising focus on cell & therapy manufacturing to support market
TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth
TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.4 LATIN AMERICA: RECESSION IMPACT
11.6 MIDDLE EAST & AFRICA
TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.1 MIDDLE EAST
11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market
TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.2 AFRICA
11.6.2.1 Favorable initiatives for R&D investments to support market growth
TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.3 REVENUE SHARE ANALYSIS
FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018?2022)
12.4 MARKET SHARE ANALYSIS
FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 PERVASIVE PLAYERS
12.5.3 EMERGING LEADERS
12.5.4 PARTICIPANTS
FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
12.5.5 COMPANY FOOTPRINT ANALYSIS
TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022)
12.5.6 PRODUCT FOOTPRINT OF COMPANIES
TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS
12.5.7 REGIONAL FOOTPRINT OF COMPANIES
TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022)
12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES
TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
12.7 COMPETITIVE SCENARIOS AND TRENDS
12.7.1 PRODUCT LAUNCHES
TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?OCTOBER 2023)
12.7.2 DEALS
TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020?OCTOBER 2023)
12.7.3 OTHER DEVELOPMENTS
TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020?OCTOBER 2023)
13 COMPANY PROFILES
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1 KEY PLAYERS
13.1.1 DANAHER CORPORATION
TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
13.1.2 SARTORIUS AG
TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022)
13.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
13.1.4 REPLIGEN CORPORATION
TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW
FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022)
13.1.5 MERCK KGAA
TABLE 249 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022)
13.1.6 3M COMPANY
TABLE 250 3M COMPANY: BUSINESS OVERVIEW
FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022)
13.1.7 GETINGE AB
TABLE 251 GETINGE AB: BUSINESS OVERVIEW
FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022)
13.1.8 EPPENDORF SE
TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW
FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022)
13.1.9 CORNING INCORPORATED
TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
13.1.10 ENTEGRIS
TABLE 254 ENTEGRIS: BUSINESS OVERVIEW
FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022)
13.1.11 FUJIFILM HOLDINGS CORPORATION
TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
13.1.12 MEISSNER FILTRATION PRODUCTS, INC.
TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW
13.1.13 KЬHNER AG
TABLE 257 KЬHNER AG: BUSINESS OVERVIEW
13.1.14 ESCO LIFESCIENCES GROUP
TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW
13.1.15 SATAKE MULTIMIX CORPORATION
TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 BIONET
13.2.2 STOBBE GROUP
13.2.3 BBI-BIOTECH GMBH
13.2.4 OMNIBRX BIOTECHNOLOGIES
13.2.5 CELL CULTURE COMPANY, LLC
13.2.6 PIERRE GUЙRIN
13.2.7 SOLIDA BIOTECH GMBH
13.2.8 ZELLWERK GMBH
13.2.9 3D BIOTEK, LLC
13.2.10 FIBERCELL SYSTEMS INC.
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SEGMENTATION
FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)
FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022)
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH FORECAST
FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023–2028)
FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 DATA TRIANGULATION & MARKET BREAKDOWN
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION)
FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET
4 PREMIUM INSIGHTS
4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW
FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT
FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION
FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2 MARKET DYNAMICS
TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising demand for biopharmaceuticals
5.2.1.2 Growing adoption among CDMOs and CMOs
5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode
5.2.1.4 Favorable regulatory & government support for innovative technologies
5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing
5.2.2 RESTRAINTS
5.2.2.1 High capital investments to limit entry for smaller players
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
5.2.3.2 PAT-enabled optimization of continuous bioprocessing
5.2.4 CHALLENGES
5.2.4.1 Integration into existing manufacturing facilities
5.2.4.2 Operational challenges
5.3 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022)
TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022)
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & PRODUCT DEVELOPMENT
5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY
5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET
TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE)
5.8 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013–SEPTEMBER 2023)
5.9 KEY CONFERENCES AND EVENTS
TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023?2024)
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2 REGULATORY GUIDELINES
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 TECHNOLOGY ANALYSIS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS
5.14 KEY BUYING CRITERIA, BY END USER
FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET
6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES
6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET
TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 FILTRATION SYSTEMS AND DEVICES
6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET
TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 BIOREACTORS
6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND
TABLE 27 BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS
6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.6 OTHER PRODUCTS
TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION
7.1 INTRODUCTION
TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
7.2 COMMERCIAL OPERATIONS
7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET
TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
7.3 CLINICAL OPERATIONS
7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET
TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS
8.1 INTRODUCTION
TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
8.2 DOWNSTREAM BIOPROCESS
8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET
TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
8.3 UPSTREAM BIOPROCESS
8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH
TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 MONOCLONAL ANTIBODIES
9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET
TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
9.3 VACCINES
9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET
TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
9.4 CELL & GENE THERAPY
9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND
TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
9.5 OTHER APPLICATIONS
TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 CONTINUOUS BIOPROCESSING MARKET, BY END USER
10.1 INTRODUCTION
TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET
TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
10.4 ACADEMIC & RESEARCH INSTITUTES
10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH
TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
11 CONTINUOUS BIOPROCESSING MARKET, BY REGION
11.1 INTRODUCTION
TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 High biopharmaceutical R&D spending to drive market
TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market
TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing initiatives for life sciences research to boost demand
TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 UK
11.3.2.1 Favorable government support for biotech clusters to propel market
TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising demand for mAbs and biologics to drive market
TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Growth in pharma & biopharma industries to boost demand
TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing R&D funding by academic institutes to support market growth
TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Government support and rising private investments to drive market growth
TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth
TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growth in pharmaceutical industry to boost demand
TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 SOUTH KOREA
11.4.4.1 Rising focus on quality manufacturing practices to drive market
TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 ASIA PACIFIC: RECESSION IMPACT
11.5 LATIN AMERICA
TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Rising focus on cell & therapy manufacturing to support market
TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth
TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.4 LATIN AMERICA: RECESSION IMPACT
11.6 MIDDLE EAST & AFRICA
TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.1 MIDDLE EAST
11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market
TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.2 AFRICA
11.6.2.1 Favorable initiatives for R&D investments to support market growth
TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.3 REVENUE SHARE ANALYSIS
FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018?2022)
12.4 MARKET SHARE ANALYSIS
FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 PERVASIVE PLAYERS
12.5.3 EMERGING LEADERS
12.5.4 PARTICIPANTS
FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
12.5.5 COMPANY FOOTPRINT ANALYSIS
TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022)
12.5.6 PRODUCT FOOTPRINT OF COMPANIES
TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS
12.5.7 REGIONAL FOOTPRINT OF COMPANIES
TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022)
12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES
TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
12.7 COMPETITIVE SCENARIOS AND TRENDS
12.7.1 PRODUCT LAUNCHES
TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?OCTOBER 2023)
12.7.2 DEALS
TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020?OCTOBER 2023)
12.7.3 OTHER DEVELOPMENTS
TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020?OCTOBER 2023)
13 COMPANY PROFILES
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1 KEY PLAYERS
13.1.1 DANAHER CORPORATION
TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
13.1.2 SARTORIUS AG
TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022)
13.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
13.1.4 REPLIGEN CORPORATION
TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW
FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022)
13.1.5 MERCK KGAA
TABLE 249 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022)
13.1.6 3M COMPANY
TABLE 250 3M COMPANY: BUSINESS OVERVIEW
FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022)
13.1.7 GETINGE AB
TABLE 251 GETINGE AB: BUSINESS OVERVIEW
FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022)
13.1.8 EPPENDORF SE
TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW
FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022)
13.1.9 CORNING INCORPORATED
TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW
FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
13.1.10 ENTEGRIS
TABLE 254 ENTEGRIS: BUSINESS OVERVIEW
FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022)
13.1.11 FUJIFILM HOLDINGS CORPORATION
TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
13.1.12 MEISSNER FILTRATION PRODUCTS, INC.
TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW
13.1.13 KЬHNER AG
TABLE 257 KЬHNER AG: BUSINESS OVERVIEW
13.1.14 ESCO LIFESCIENCES GROUP
TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW
13.1.15 SATAKE MULTIMIX CORPORATION
TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 BIONET
13.2.2 STOBBE GROUP
13.2.3 BBI-BIOTECH GMBH
13.2.4 OMNIBRX BIOTECHNOLOGIES
13.2.5 CELL CULTURE COMPANY, LLC
13.2.6 PIERRE GUЙRIN
13.2.7 SOLIDA BIOTECH GMBH
13.2.8 ZELLWERK GMBH
13.2.9 3D BIOTEK, LLC
13.2.10 FIBERCELL SYSTEMS INC.
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
